GlassScriptPhysician profile
Violeta D Avramov
NPI 1184662876
$3,548.41
in general payments reported to CMS, 2019-2025
40 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $183 · 2021: $350 · 2022: $582 · 2023: $497 · 2024: $796 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.37 | 2021-2025 | Botox, Qulipta |
| Teva Pharmaceuticals USA, INC. | $425.37 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $403.66 | 2023-2025 | |
| Lilly USA, LLC | $337.13 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Biohaven Pharmaceutical Holding Company LTD. | $200.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $163.58 | 2020-2024 | Ultomiris |
| Biogen, INC. | $117.01 | 2019-2024 | Vumerity, Tysabri |
| Ucb, INC. | $95.61 | 2019-2024 | Rystiggo |
| Eisai INC. | $79.16 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $77.77 | 2021 | |
| Neurocrine Biosciences, INC. | $75.47 | 2024-2025 | Ingrezza |
| Celgene Corporation | $74.12 | 2022-2023 | Zeposia |
| Emd Serono, INC. | $72.66 | 2019-2023 | Mavenclad |
| Impel Pharmaceuticals INC. | $63.16 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $54.52 | 2024-2025 | Rexulti, Nuedexta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Violeta Avramov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.